Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Under the proposed legislation, which would amend title 18 of the Social Security Act, starting in 2021, HHS would add a new set of measures to the current 5-star rating system based on biosimilar access in Part B and, for MA plans that offer prescription drug coverage, in Part D.
The measures include assessing the following: whether a biosimilar is on the formulary in lieu of or in addition to the reference, tier placement or cost-sharing for biosimilars relative to the reference, whether and how utilization management is applied, and the percentage of enrollees prescribed biosimilars rather than references.
The bill has now been referred to the Committee on Energy and Commerce and the Committee on Ways and Means.
According to a statement by Tonko, “certain profitable dynamics in America’s health care system are blocking access to these cost saving alternatives, meaning our patients and their families are forced to pay a higher price for substantially similar medical care. My bill will highlight the existing barriers in current health plans, provide for meaningful transparency where plans fall short, and allow for reform to unlock the billions in savings for America’s patients and taxpayers."
Trade group the Biosimilars Forum praised the provisions, saying in a statement on the bill that “CMS must take this opportunity to save seniors and taxpayers money. Congressmen Tonko and Gibbs understand the importance of identifying inefficiencies in health plans that are blocking patient access and use of lower-cost biosimilars to treat some of life’s most complex illnesses. Through this measurement, it will allow for reforms that will encourage health plans to drive significant savings in health care.”
In the Senate, parallel provisions have been put forth under S.2543, or the Prescription Drug Pricing Reduction Act of 2019, sponsored by Senator Chuck Grassley, R-Iowa. The Senate bill was introduced in the Senate in September, and which has been placed on the Senate legislative calendar under general orders.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.